HeartBeam, Inc. announced that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office. HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG. The first patent, "Mobile three-lead cardiac monitoring device and method for automated diagnostics" covers amaratuses and methods that facilitate the comparison of cardiac signals over time for the automated or assisted detection of heart attacks, or Acute Myocardial Infarction (AMI).

For each patient, HeartBeam provides a comparative baseline ECG which aids physicians in gaining richer insights about the patient's cardiac health. This approach was validated in a landmark JACC: Advances publication which demonstrated that HeartBeam's VECG approach with a comparative baseline had significantly higher diagnostic accuracy (95% Area Under the Curve or AUC) than a 12-lead ECG alone (68% AUC). The second patent, "Apparatus for generating an electrocardiogram" covers methods and apparatuses around HeartBeam's wrist-based ECG system.

This is the second patent related to HeartBeam's watch concept, which combines a continuous ECG monitor with the ability to take a high sensitivity 12-lead ECG - all in a single device designed to be worn on the wrist. In addition to the 14 issued and allowed U.S patents and 4 international patents, HeartBeam has 20 pending applications worldwide. These patents cover the core inventions in HeartBeam's V ECG technology, as well as the specific applications across HeartBeam's product portfolio, including patient carried devices (HeartBeam AIMIGo??, continuous monitors (LIVMOR), extended wear patches, and watch-based 12-lead ECGs.